BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
Credit Suisse maintains neutral on Dr Reddy's Lab
Key investor question is the worst case priced in? Worst-case scenario is FY17 estimated earnings per share could be flattish. Expect 15 per cent downside in worst case. Higher competition in Valcyte & Vidaza are risks. Estimates under review till warning letter details released.